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Background: Only a few studies have compared these devices for safety, complications, mortality, and recurrence of stroke, transient ischemic 
attack (TIA) and arrhythmia. We compared current devices for patent foramen ovale (PFO) closure with respect to procedural complications, residual 
shunt, and clinical outcome. 
Methods: We studied 114 consecutive patients who had PFO closure for various reasons (85% cryptogenic stroke). Amplatzer® PFO device (AGA 
Medical Corp., Plymouth, MN) versus CardioSEAL/STARflex® device (NMT Medical Inc., Boston, MA) versus Gore Helex device (W.L. Gore & Associates 
Inc., Flagstaff, AZ) were compared (Table). 
Results: Closure was equally successful for all devices. Clinical follow-up was completed in 95% of patients. There was no significant difference 
in rate of periprocedural complications, recurrence of TIA/stroke, or arrhythmia. One death related to closure occurred in each Amplatzer PFO 
(Hemothorax) and STARflex (retrocardiac hematoma) group. Immediate periprocedural shunts (mostly small) were more common in the Amplatzer 
PFO and Gore Helex devices. 
Conclusions: Most closure devices in the market have comparable safety and efficacy rates. Immediate post procedural residual small shunts 
were more commonly observed in Amplatzer PFO and Gore Helex devices. Results showed a higher out-of-hospital mortality rate associated with 
Amplatzer PFO device. 
Outcome by Device in Patients With PFO
TYPE OF DEVICE
CHARACTERISTIC
Amplatzer PFO; n=30
No. (%)
CardioSEAL/STARflex; n=71
No. (%)
Gore Helex; n=13
No. (%)
p-Value
Demographics
Age - mean ± SD years 57.6±16.56 52.1±14.35 54.1±11.59 NS
Female 12 (40.0%) 29 (40.9%) 7 (53.9%) NS
TIA 18 (60.0%) 38 (53.5%) 4 (30.8%) NS
Stroke 17 (56.7%) 37 (52.1%) 8 (61.5%) NS
Arrhythmia 3 (10.0%) 5 (7.0%) 1 (7.7%) NS
Median follow-up - months (IQR) 15 (3-23) 19 (7-36) 5 (3-24) NS
Device size - mean ± SD mm 25.8±5.39 25.5±4.04 26.5±4.47 NS
Procedural Success 30 (100%) 70 (98.6%) 13 (100%) NS
Post Procedural Shunt
Small 6 (20.0%) 3 (4.2%) 3 (23.1%) <0.05Moderate/Large 0 (0.0%) 2 (2.8%) 1 (7.7%)
Complication 1 (3.3%) 1 (1.4%) 0 (0.0%) NS
Death 5 (16.7%) 1 (1.4%) 0 (0.0%) <0.05
In-hospital 1 (3.3%) 1 (1.4%) 0 (0.0%) <0.05Out-of-hospital 4(13.3%) 0(0.0%) 0(0.0%)
Recurrent Event (follow-up)
TIA 3 (10.0%) 4 (5.6%) 1 (7.7%) NS
Stroke 0 (0.0%) 2 (2.8%) 0 (0.0%) NS
Arrythmia 4 (13.3%) 4 (5.6%) 2 (15.4%) NS
Abbreviations: IQR=interquartile range; PFO= patent foramen ovale; TIA=transient ischemic attack.
